FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313334015> ?p ?o ?g. }

• W4313334015 endingPage "152322" @default.
• W4313334015 startingPage "152322" @default.
• W4313334015 abstract "IL-38 is a newly identified cytokine that exhibits immunosuppression effects. However, there are few studies focusing on the effects and mechanisms of IL-38 in the systemic lupus erythematosus (SLE).We investigated the effects and mechanisms of IL-38 on NF-κB signaling pathway in SLE.Levels of IL-38, IL-36R, IL-1RAcP, IKKα/β, NF-κB, TNF-α and anti-dsDNA antibody levels in peripheral blood of SLE patients, and in peripheral blood and kidney tissues of MRL/lpr mice, were examined with real-time PCR, ELISA, Western blot and immunohistochemistry. Pathological changes of kidney were detected with PAS staining. Recombinant human IL-38 protein and IL-38 siRNA were used to intervene the PBMCs of SLE patients and MRL/lpr mice.The mRNA and protein levels of IL-38 in peripheral blood of SLE patients decreased and were positively correlated. The mRNA and protein levels of IKKα/β, NF-κB, and TNF-α increased, especially in patients with active SLE. There was a negative correlation between IL-38 and the levels of IKKα/β, NF-κB and TNF-α in SLE patients. In vitro experiments showed that the levels of IKKα/β, NF-κB and TNF-α, and anti-dsDNA antibodies decreased in PBMCs of SLE patients after treatment with human recombinant IL-38 protein. These effects were reversed after IL-38 siRNA intervention. Consistent results were obtained on IL-38, IKKα/β, NF-κB, and TNF-α in MRL/lpr lupus mice after treatment with IL-38 protein or IL-38 shRNA. Additionally, kidney function (reflected by creatinine and blood urea nitrogen), anti-dsDNA antibody, complement C3, and urinary protein levels decreased after treatment with IL-38 protein but increased after IL-38 shRNA treatment. PAS staining showed IL-38 protein treatment induced mild hyperplasia of glomerular mesangial cells and a small amount of lymphocyte infiltration. However, these were aggravated after IL-38 shRNA treatment.IL-38 may be involved in the occurrence and development of SLE by regulating the NF-κB signaling pathway. This study only discussed the relationship between IL-38 and NF-κB, and more biological functions of IL-38 need to be further studied." @default.
• W4313334015 created "2023-01-06" @default.
• W4313334015 creator A5003898556 @default.
• W4313334015 creator A5006974530 @default.
• W4313334015 creator A5055913309 @default.
• W4313334015 creator A5060853768 @default.
• W4313334015 date "2023-03-01" @default.
• W4313334015 modified "2023-09-30" @default.
• W4313334015 title "Regulatory effect of IL-38 on NF-κB pathway in systemic lupus erythematosus" @default.
• W4313334015 cites W1970338050 @default.
• W4313334015 cites W1976682338 @default.
• W4313334015 cites W2006140590 @default.
• W4313334015 cites W2020619427 @default.
• W4313334015 cites W2028141281 @default.
• W4313334015 cites W2042132770 @default.
• W4313334015 cites W2042773778 @default.
• W4313334015 cites W2051771323 @default.
• W4313334015 cites W2052943307 @default.
• W4313334015 cites W2062778102 @default.
• W4313334015 cites W2067591914 @default.
• W4313334015 cites W2069676201 @default.
• W4313334015 cites W2079049654 @default.
• W4313334015 cites W2090197666 @default.
• W4313334015 cites W2097504851 @default.
• W4313334015 cites W2099667986 @default.
• W4313334015 cites W2110440735 @default.
• W4313334015 cites W2115234798 @default.
• W4313334015 cites W2122044177 @default.
• W4313334015 cites W2163347620 @default.
• W4313334015 cites W2163822663 @default.
• W4313334015 cites W2167314990 @default.
• W4313334015 cites W2188988854 @default.
• W4313334015 cites W2189790494 @default.
• W4313334015 cites W2536639665 @default.
• W4313334015 cites W2789797871 @default.
• W4313334015 cites W2890427079 @default.
• W4313334015 cites W2921781976 @default.
• W4313334015 cites W2999065750 @default.
• W4313334015 cites W4379365691 @default.
• W4313334015 doi "https://doi.org/10.1016/j.imbio.2022.152322" @default.
• W4313334015 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36621308" @default.
• W4313334015 hasPublicationYear "2023" @default.
• W4313334015 type Work @default.
• W4313334015 citedByCount "1" @default.
• W4313334015 countsByYear W43133340152023 @default.
• W4313334015 crossrefType "journal-article" @default.
• W4313334015 hasAuthorship W4313334015A5003898556 @default.
• W4313334015 hasAuthorship W4313334015A5006974530 @default.
• W4313334015 hasAuthorship W4313334015A5055913309 @default.
• W4313334015 hasAuthorship W4313334015A5060853768 @default.
• W4313334015 hasConcept C104317684 @default.
• W4313334015 hasConcept C126322002 @default.
• W4313334015 hasConcept C134018914 @default.
• W4313334015 hasConcept C137061746 @default.
• W4313334015 hasConcept C159654299 @default.
• W4313334015 hasConcept C17991360 @default.
• W4313334015 hasConcept C187316574 @default.
• W4313334015 hasConcept C202751555 @default.
• W4313334015 hasConcept C203014093 @default.
• W4313334015 hasConcept C2775915377 @default.
• W4313334015 hasConcept C2776415932 @default.
• W4313334015 hasConcept C2776912625 @default.
• W4313334015 hasConcept C2776914184 @default.
• W4313334015 hasConcept C2777730290 @default.
• W4313334015 hasConcept C2778690821 @default.
• W4313334015 hasConcept C2779134260 @default.
• W4313334015 hasConcept C2779912601 @default.
• W4313334015 hasConcept C2780091579 @default.
• W4313334015 hasConcept C55493867 @default.
• W4313334015 hasConcept C71924100 @default.
• W4313334015 hasConcept C86803240 @default.
• W4313334015 hasConceptScore W4313334015C104317684 @default.
• W4313334015 hasConceptScore W4313334015C126322002 @default.
• W4313334015 hasConceptScore W4313334015C134018914 @default.
• W4313334015 hasConceptScore W4313334015C137061746 @default.
• W4313334015 hasConceptScore W4313334015C159654299 @default.
• W4313334015 hasConceptScore W4313334015C17991360 @default.
• W4313334015 hasConceptScore W4313334015C187316574 @default.
• W4313334015 hasConceptScore W4313334015C202751555 @default.
• W4313334015 hasConceptScore W4313334015C203014093 @default.
• W4313334015 hasConceptScore W4313334015C2775915377 @default.
• W4313334015 hasConceptScore W4313334015C2776415932 @default.
• W4313334015 hasConceptScore W4313334015C2776912625 @default.
• W4313334015 hasConceptScore W4313334015C2776914184 @default.
• W4313334015 hasConceptScore W4313334015C2777730290 @default.
• W4313334015 hasConceptScore W4313334015C2778690821 @default.
• W4313334015 hasConceptScore W4313334015C2779134260 @default.
• W4313334015 hasConceptScore W4313334015C2779912601 @default.
• W4313334015 hasConceptScore W4313334015C2780091579 @default.
• W4313334015 hasConceptScore W4313334015C55493867 @default.
• W4313334015 hasConceptScore W4313334015C71924100 @default.
• W4313334015 hasConceptScore W4313334015C86803240 @default.
• W4313334015 hasFunder F4320322966 @default.
• W4313334015 hasFunder F4320328898 @default.
• W4313334015 hasIssue "2" @default.
• W4313334015 hasLocation W43133340151 @default.
• W4313334015 hasLocation W43133340152 @default.
• W4313334015 hasOpenAccess W4313334015 @default.

• next